In other words, many popular claims remain unfounded – and overlook the fact that there's a difference between CBD that's studied in labs for particular conditions and CBD products that are sold to consumers for general well-being. "What happens is people say, 'Look, CBD is harmless and it doesn't get me intoxicated, so I'm going to take it for what ails me," says Dr. Jordan Tishler, a Harvard physician and CEO of InhaleMD, a Boston-area practice specializing in cannabis therapeutics. "Then they're going to get some perceived benefit because that's the way the placebo effect works, and then they go and trumpet this."
By formulating our products with pure, full-spectrum hemp oil, we ensure that all the cannabinoids naturally found in the plant are in the hemp oil you buy from us. This also allows the cannabinoids to interact with the endocannabinoid system in what has become known as the entourage effect: when all the ingredients in hemp oil, including the terpenes, vitamins, and range of cannabinoids are allowed to work with the body naturally, as they would in the natural plant.
In response to the FDA’s historic decision, the Drug Enforcement Administration (DEA) announced in September 2018 that it had removed Epidiolex from Schedule I classification, a category reserved for dangerous drugs with no medical value. Henceforth, Epidiolex would be considered a Schedule V drug, the least dangerous designation under the Controlled Substances Act.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
×